If you have been reading about animal model and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-05. Numbers and descriptions here follow the published literature rather than marketing material.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
== Z == Shuguang Zhang (PhD 1988). American biochemist at the Massachusetts Institute of Technology, known for his discovery of self-assembling peptides. Guggenheim Fellow and Member, Austrian Academy of Sciences. Donald Zilversmit (1919–2010). Dutch-American nutritional biochemist at Cornell University, with many contributions to the understanding of the relationship between diet and cardiovascular disease. Member Natl. Acad. Sci. USA.
=== Activism === Kardashian supports the recognition of the Armenian genocide and has visited Tsitsernakaberd, the memorial to the victims in Yerevan, Armenia. In April 2021, Kardashian praised President Joe Biden for officially recognizing the Armenian Genocide, thus becoming the first US president to do so. In October 2020, Kardashian spoke out in support of Republic of Artsakh and Armenians, condemning Azerbaijan's involvement in the 2020 Nagorno-Karabakh conflict. On October 10, 2020, she spoke on the ArmeniaFund fundraising telethon and urged viewers to donate money to help those impacted by the recent war.
The linear ion trap (LIT) is a type of ion trap mass spectrometer. In a LIT, ions are confined radially by a two-dimensional radio frequency (RF) field, and axially by stopping potentials applied to end electrodes. LITs have high injection efficiencies and high ion storage capacities.
=== Actinium-227 === Actinium-227 is the most stable isotope of actinium, with a half-life of 21.772 years. It mainly (98.62%) undergoes beta decay, but sometimes (1.38%) it will undergo alpha decay instead. 227Ac is a member of the actinium series. It is found only in traces in uranium ores – one tonne of uranium in ore contains about 0.2 milligrams of 227Ac. 227Ac is prepared, in milligram amounts, by the neutron irradiation of 226Ra in a nuclear reactor.
Sources: en.wikipedia.org
=== Bacterial toxins === Bacterial ADP-ribosylating exotoxins (bAREs) covalently transfer an ADP-ribose moiety of NAD+ to target proteins of infected eukaryotes, to yield nicotinamide and a free hydrogen ion. bAREs are produced as enzyme precursors, consisting of a "A" and "B" domains: the "A" domain is responsible for ADP-ribosylation activity; and, the "B" domain for translocation of the enzyme across the membrane of the cell. These domains can exist in concert in three forms: first, as single polypeptide chains with A and B domains covalently linked; second, in multi-protein complexes with A and B domains bound by non-covalent interactions; and, third, in multi-protein complexes with A and B domains not directly interacting, prior to processing.
On September 12–17, 2013, at the 2013 IBC Conference in Amsterdam, Nagra introduced an Ultra HD User Interface called Project Ultra based on HTML5, which works with OpenTV 5. On October 4, 2013, DigitalEurope announced the requirements for their UHD logo in Europe. The DigitalEurope UHD logo requires that the display support a resolution of at least 3840 × 2160, a 16∶9 aspect ratio, the Rec. 709 (HDTV) color space, 8 bpc color depth, a frame rate of 24, 25, 30, 50, or 60 fps, and at least 2-channel audio. On October 29, 2013, Elemental Technologies announced support for real-time 4K Ultra HD HEVC video processing. Elemental provided live video streaming of the 2013 Osaka Marathon on October 27, 2013, in a workflow designed by K-Opticom, a telecommunications operator in Japan. Live coverage of the race in 4K Ultra HD was available to viewers at the International Exhibition Center in Osaka. This transmission of 4K Ultra HD HEVC video in real-time was an industry-first. On November 28, 2013, Organizing Committee of the XXII Olympic Winter Games and XI Paralympic Winter Games 2014 in Sochi chief Dmitri Chernyshenko stated that the 2014 Olympic Winter Games would be shot in 8K Super Hi-Vision. On December 25, 2013, YouTube added a "2160p 4K" option to its videoplayer. Previously, a visitor had to select the "original" setting in the video quality menu to watch a video in 4K resolution. With the new setting, YouTube users can much more easily identify and play 4K videos.
==== MeSH D12.125.072 – amino acids, cyclic ==== MeSH D12.125.072.050 – amino acids, aromatic MeSH D12.125.072.050.342 – dextrothyroxine MeSH D12.125.072.050.685 – phenylalanine MeSH D12.125.072.050.685.400 – dihydroxyphenylalanine MeSH D12.125.072.050.685.400.180 – cysteinyldopa MeSH D12.125.072.050.685.400.500 – levodopa MeSH D12.125.072.050.685.400.600 – methyldopa MeSH D12.125.072.050.685.440 – fenclonine MeSH D12.125.072.050.685.450 – p-fluorophenylalanine MeSH D12.125.072.050.685.500 – melphalan MeSH D12.125.072.050.767 – thyroxine MeSH D12.125.072.050.767.741 – thyronines MeSH D12.125.072.050.767.741.180 – diiodothyronines MeSH D12.125.072.050.767.741.894 – triiodothyronine MeSH D12.125.072.050.767.741.947 – triiodothyronine, reverse MeSH D12.125.072.050.850 – tryptophan MeSH D12.125.072.050.850.479 – 5-hydroxytryptophan MeSH D12.125.072.050.875 – tyrosine MeSH D12.125.072.050.875.064 – betalains MeSH D12.125.072.050.875.064.500 – betacyanins MeSH D12.125.072.050.875.130 – dihydroxyphenylalanine MeSH D12.125.072.050.875.130.180 – cysteinyldopa MeSH D12.125.072.050.875.130.500 – levodopa MeSH D12.125.072.050.875.130.600 – methyldopa MeSH D12.125.072.050.875.262 – diiodotyrosine MeSH D12.125.072.050.875.379 – melanins MeSH D12.125.072.050.875.496 – monoiodotyrosine MeSH D12.125.072.050.875.664 – methyltyrosines MeSH D12.125.072.050.875.664.050 – alpha-methyltyrosine MeSH D12.125.072.050.875.750 – phosphotyrosine MeSH D12.125.072.170 – cycloleucine MeSH D12.125.072.200 – desmosine MeSH D12.125.072.329 – histidine MeSH D12.125.072.329.269 – ergothioneine MeSH D12.125.072.329.539 – methylhistidines MeSH D12.125.072.401 – imino acids MeSH D12.125.072.401.200 – azetidinecarboxylic acid MeSH D12.125.072.401.623 – proline MeSH D12.125.072.401.623.270 – captopril MeSH D12.125.072.401.623.374 – fosinopril MeSH D12.125.072.401.623.478 – hydroxyproline MeSH D12.125.072.401.761 – pyrrolidonecarboxylic acid MeSH D12.125.072.401.830 – technetium tc 99m diethyl-iminodiacetic acid MeSH D12.125.072.401.840 – technetium tc 99m disofenin MeSH D12.125.072.401.900 – technetium tc 99m lidofenin MeSH D12.125.072.415 – isodesmosine
Sources: en.wikipedia.org
== Function == The cell bodies produce the peptide hormone vasopressin, which is also known as anti-diuretic hormone (ADH), and the peptide hormone oxytocin. Both of these peptides are released from the posterior pituitary. ADH travels via the bloodstream to its target cells in the papillary ducts in the kidneys, enhancing water reabsorption. Oxytocin travels via the bloodstream to act at the mammary glands and the uterus. In the cell bodies, the hormones are packaged in large, membrane-bound vesicles that are transported down the axons to the nerve endings. The secretory granules are also stored in packets along the axon called Herring bodies. Similar magnocellular neurons are also found in the paraventricular nucleus.
For convenience, three different views of the data are available on Wikipedia: two sets of "segmented tables", and a single "unitized table (all elements)". The unitized table allows easy visualization of proton/neutron-count trends but requires simultaneous horizontal and vertical scrolling. The segmented tables permit easier examination of a particular chemical element with much less scrolling. Links are provided to quickly jump between the different sections.
For instance, cows and buffalo udders have two pairs of mammary glands and four teats, whereas sheep and goat udders have one pair of mammary glands with two teats protruding from the udder. Each mammary gland produces milk for a single teat and is evolutionarily derived from modified sweat glands.
=== Discovery, regulation and marketing === Docetaxel is marketed worldwide under the name Taxotere by Sanofi-Aventis as well as Docefrez by Sun Pharma Global and Zytax by Zydus. Annual sales of Taxotere in 2010 were €2.122 billion (US$3.1 billion). The patent expired in 2010. Docetaxel was developed by Rhône-Poulenc Rorer (now Sanofi-Aventis) following from the discoveries of Pierre Potier at CNRS at Gif-sur-Yvette during his work on improvements to the production of paclitaxel (Taxol) using the local European yew.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.